Exclusive: Global trial finds treatment with amivantamab and lazertinib halts progression for average of 23.7 months
Doctors are hailing “amazing” trial results that show a new drug combination stopped lung cancer advancing for more than 40% longer than the standard treatment.
Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8 million deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.
About Author
More Stories
As a geneticist, I will not mourn 23andMe and its jumble of useless health information | Adam Rutherford
Trump extends deadline for TikTok sale to non-Chinese buyer to avoid ban
Secret to stronger pour-over coffee with no extra beans unlocked by scientists